Confocal microscopy as an evaluation tool of wound healing in corneal surgery

Article

Confocal microscopy as an evaluation tool of wound healing in corneal surgery

Confocal Microscopy will remain an essential tool to evaluate corneal healing, long-term stability and complications in new refractive procedures, Dr. Maria João Quadrado told delegates yesterday.

“With confocal microscopy we can visualize and quantify corneal structures, infectious organisms, and inflammatory cells,” she said.

“We can visualize and quantify corneal infiltrates after refractive surgery, whether they are infectious or inflammatory,” she added.

She said it can establish the depth of LASIK flaps and it can be used to visualize and quantify epithelial in the anterior chamber, and epithelial cells in the endothelium.

Dr. Quadrado began with an overview of the technology and the scope of its applications, noting its relevance to wound healing for any procedure, whether LASIK, PRK, PK, DSAEK, DLAK or others.

Confocal Microscopy is an important tool for studying cystic diseases, dystrophy, graft rejection, deposits, or microorganisms like acanthamoeba or fungus.

A particular strength is its ability to deliver images from every level, from superficial epithelium to basal cells, the anterior and posterior stroma and the endothelium. It was a key technology in many studies and the means for new insights to old problems.

She noted that confocal studies had help show that reflective particle density at the flap interface did not correlate with flap thickness, haze intensity or ablation depth. It has shown that particles can have variable size and reflectivity, particles decrease with time and stabilise at six months.

Dr. Quadrado next surveyed briefly the impact of confocal microscopy on our understanding of wound healing for certain procedures, and illustrated how the technique can characterise the wound healing profiles of different techniques. It will, she concluded, remain an essential tool.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.